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https://doi.org/10.1016/j.stemcr.2017.12.018SUMMARYPerturbations in stress granule (SG) dynamics may be at the core of amyotrophic lateral sclerosis (ALS). Since SGs are membraneless
compartments, modeling their dynamics in human motor neurons has been challenging, thus hindering the identification of effective
therapeutics. Here, we report the generation of isogenic induced pluripotent stem cells carrying wild-type and P525L FUS-eGFP. We
demonstrate that FUS-eGFP is recruited into SGs and that P525L profoundly alters their dynamics. With a screening campaign, we
demonstrate that PI3K/AKT/mTOR pathway inhibition increases autophagy and ameliorates SG phenotypes linked to P525L FUS by
reducing FUS-eGFP recruitment into SGs. Using aDrosophilamodel of FUS-ALS, we corroborate that induction of autophagy significantly
increases survival. Finally, by screening clinically approved drugs for their ability to ameliorate FUS SG phenotypes, we identify a number
of brain-penetrant anti-depressants and anti-psychotics that also induce autophagy. These drugs could be repurposed as potential ALS
treatments.INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal de-
mentia (FTD) are neurodegenerative diseases characterized
by progressive neurodegeneration and protein aggregation.
In ALS, upper and lower motor neurons (MNs) degenerate,
causing paralysis and death. In FTD, cerebral neurons
degenerate to cause early-onset dementia. Although rilu-
zole and edaravone are used for treating ALS, they only
partially slow disease progression (Sawada, 2017; Writing
Group and Edaravone (MCI-186) ALS 19 Study Group,
2017). Similarly, no medications specifically prevent or
effectively slow FTD, thus effective therapies are urgently
needed.
Genetics and neuropathology link ALS and FTD. About
10% of ALS cases are familial (fALS) and mostly caused by
autosomal dominant genetic mutations. As the third
most common monogenetic form of ALS is associated
with FUS mutations, FUS has aroused considerable interest
among researchers. In its wild-type (WT) form, the FUS pro-
tein interacts with components of the splicing machinery,
binds and processes RNA, and shuttles between nucleus
and cytoplasm for mRNA export and stress granule (SG)Stem Cell Re
This is an open access article under the Cformation (Dormann et al., 2010). Mutations causing
FUS-ALS primarily occur in two domains: the prion-like
domain and the nuclear localization signal (NLS). NLS
mutations, including P525L, which results in a severe
early-onset form of ALS (Conte et al., 2012), cause aberrant
localization of FUS to the cytoplasm (Dormann et al.,
2010). Aggregates of FUS are a hallmark of FUS-ALS, but
the dynamics of their formation are poorly understood.
Significantly, cytoplasmic FUS aggregates are also found
in FTD patients (Neumann et al., 2009), most of whom
lack FUS mutations, demonstrating that disruption of FUS
nuclear transport can occur even in the absence of muta-
tions, perhaps by FUS protein misfolding.
Recent evidence suggests that SGs (non-membrane-
bound compartments of regulated protein aggregation
upon stress) may act as nucleation centers for the forma-
tion of insoluble aggregates in pathological conditions.
FUS is recruited to SGs by its prion-like domain, and muta-
tions in this domain promote FUS aggregation, resulting in
liquid-to-solid phase transition. Other ALS-associated
proteins behave similarly to FUS, including TAR DNA
binding protein (TARDBP/TDP43), Ataxin2 (ATX2), TATA-
box binding protein-associated factor 15 (TAF15), Ewingports j Vol. 10 j 375–389 j February 13, 2018 j ª 2018 The Authors. 375
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
sarcoma RNA binding protein 1 (EWSR1), Heterogeneous
nuclear ribonucleoprotein A1 (HNRNPA1), and Heteroge-
neous nuclear ribonucleoprotein A2B1 (HNRNPA2B1).
These contain prion domains, can be recruited to SGs,
and are prone to protein aggregation when mutated.
Similar to FUS, genetics and neuropathology studies show
that TDP43, EWSR1, and TAF15 are linked to FTD (Macken-
zie et al., 2010; Neumann et al., 2011), reinforcing the
observation that ALS and FTD are connected.
Misregulation of autophagy also plays a critical role in
ALS/FTD pathogenesis since disease-causing mutations
were identified in many proteins that regulate this system,
including Sequestosome 1 (SQSTM1/P62), valosin-con-
taining protein (VCP), Optineurin (OPTN), TANK binding
kinase 1 (TBK1), and chromosome 9 open reading frame
72 (C9ORF72). In addition, proteins such as heat-shock
protein B8 (HSPB8) play a dual role in SG disassembly
and promotion of autophagic removal of misfolded
proteins (Ganassi et al., 2016), suggesting a link between
autophagy and SG dynamics. Thus, compounds inducing
autophagy might protect neurons from FUS pathology.
However, the mechanism linking autophagy, SGs, and
ALS pathogenesis is unclear, significantly impeding the
identification of effective drugs for ALS/FTD.
The inability to directly probe patient MNs has
hampered ALS research, and studying SGs in human
neurons has been challenging due to their lack of mem-
brane. Induced pluripotent stem cells (iPSCs), capable of
immortal self-renewal and differentiation into specialized
cell types, represent an exciting tool to recapitulate the dis-
ease and study the intricate biology of neurons. Multiple
groups reported the generation of iPSCs from ALS-FUS
patients (Japtok et al., 2015; Lenzi et al., 2015) and showed
FUS to be recruited to SGs in mutant iPSC-derived MNs,
with cytoplasmic aggregates manifesting upon increased
neuronal aging (Japtok et al., 2015). However, the ability
to monitor FUS and SG dynamics in human neurons in
real time was still lacking.
Here, we report the generation of WT and P525L
FUS-eGFP reporter iPSC lines using CRISPR/Cas9n-medi-
ated gene editing. We confirm that the P525L mutation
in the NLS domain causes mislocalization of FUS-eGFP
protein to the cytoplasm and that FUS-eGFP is incorpo-
rated into SGs upon oxidative stress induction via arsenite
treatment (Japtok et al., 2015). Even without stress, P525L
FUS-GFP spontaneously formed puncta, particularly in
cells expressing a variant of FUS-eGFP leading to exacer-
bated cytoplasmic mislocalization, and which we demon-
strate were subcellular structures distinct from SGs.
Although WT and mutant FUS-eGFP proteins are both
recruited to SGs in our system, we show that SGs in iPSCs
and iPSC-derived neuronal cultures with P525L FUS-eGFP
contained more FUS-eGFP. With a phenotypic screening376 Stem Cell Reports j Vol. 10 j 375–389 j February 13, 2018campaign, we identified inhibitors of the PI3K/AKT/
mTOR pathway that reduced FUS-eGFP recruitment to
iPSC SGs. Rapamycin, a well-characterizedmTOR inhibitor
and autophagy inducer, rescued the P525L FUS-linked SG
phenotype in iPSCs and iPSC-derived neurons, although
the response in neuronal cultures was delayed and weaker
compared with iPSCs. The potent and direct ATP compet-
itor torkinib rapidly ameliorated FUS SG phenotypes in
neurons more efficiently. Using a Drosophila model of
FUS-ALS, we further validated that autophagy induction
significantly increases survival. As proof of principle, we
further screened a library of clinically approved drugs and
found that anti-depressants and anti-psychotics known
to also induce autophagy ameliorated the FUS SG pheno-
type, suggesting they could be repurposed as ALS treat-
ments. We conclude that the combination of isogenic
reporter iPSCs with compound screening is a powerful
tool to identify novel ALS drugs.RESULTS
Generation of WT and P525L FUS-eGFP Reporter iPSC
Lines
To study the molecular mechanisms of FUS-ALS, we gener-
ated isogenic FUS-eGFP reporter lines (Figure 1A). For this,
we used WT iPSC lines that had been previously derived
and characterized from healthy donors (details in Supple-
mental Information). Cells were transiently transfected
for CRISPR-mediated gene editing with a plasmid contain-
ing Cas9n and two single guide RNAs to introduce two
opposing nicks within the last intron of the FUS gene (Fig-
ures 1A and S1A). Simultaneously, we provided a donor
construct (Figure S1A) containing a long and well-charac-
terized linker, which would prevent the eGFP tag from
interfering with FUS protein folding (Figure 1B). One of
the donor constructs included C1679T, which encodes
the P525L mutation known to cause a severe form of
FUS-fALS. Genotyping showed targeted integration of the
eGFP reporter sequence (Figure S1B). Sequencing of the
edited region confirmed the presence of the P525L muta-
tion in mutant lines and excluded incorporation of
unwanted mutations at the FUS-eGFP junction site in
both WT and mutant lines (Figure S1C). Immunostaining
proved that gene-edited iPSCs maintained expression of
the pluripotency markers OCT4, SOX2, and SSEA4 (Fig-
ure S1F). Finally, metaphase spread analysis showed
euploidy (Figure S2).
P525L lies in the NLS of FUS protein, and ALS mutations
in the NLS domain were reported to cause FUS proteinmis-
localization to the cytoplasm (Dormann et al., 2010). Thus,
we used fluorescence microscopy to examine the localiza-
tion of WT and P525L FUS-eGFP. WT FUS-eGFP primarily
HBA
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Figure 1. Generation of FUS-eGFP Re-
porter iPSCs
(A–F) Examples of FUS gene before and after
gene editing to insert eGFP (A). Cas9n cut
sites are shown with locations of primers
used for genotyping. Schematic represen-
tation of the linkers used to knock in eGFP
in LL (B) and SL (E) iPSC lines. Confocal
micrographs showing FUS localization in WT
and P525L FUS-eGFP cells for LL (C) and SL
(F). Nuclear and cytoplasmic segmentation
is displayed. Scale bar, 10 mm. (D) Quanti-
fication of the FUS-eGFP cytoplasmic-nu-
clear ratio in WT and P525L FUS-eGFP LL and
SL iPSCs. All values are expressed as fold
relative to LL WT FUS-eGFP iPSCs. Data
represent results from three independent
measurements. Error bars indicate SD.
**p < 0.01 and ****p < 0.0001.
(G–I) qRT-PCR showing total FUS RNA levels
(G). WB and relative quantification using an
anti-FUS antibody showing expression of
FUS and FUS-eGFP in LL (H) and SL (I) iPSCs.
Results are shown for two different WT and
P525L lines as biological replicates and
were reproduced in three independent ex-
periments. Error bars indicate SD.localized to the nucleus (Figure 1C). Consistent with
previous reports, P525L FUS-eGFP had increased cyto-
plasmic localization, with substantial FUS-eGFP still de-
tected in the nucleus (Figure 1C). Quantification of the
cytoplasmic-nuclear ratio revealed a 4-fold increase of cyto-
plasmic FUS-eGFP in P525L iPSC lines compared with WT
(Figure 1D).
Because FTD is associated with cytoplasmic aggregation
of WT FUS, we speculated that further impairing the
nuclear localization of FUS may exacerbate disease pa-
thology, which could be a considerable advantage for dis-
ease modeling considering the typically late onset of ALS
and FTD. For this reason, we generated a second set of
iPSC reporter lines carrying a shorter linker stretch (Fig-ure 1E), which we speculated would increase aberrant
cytoplasmic localization by disrupting the interaction
with nuclear transport receptors such as Transportin
and/or interfering with FUS folding, particularly consid-
ering proximity to the adjacent NLS. Genotyping and
sequencing demonstrated successful editing. Immuno-
staining showed maintenance of pluripotent markers,
and metaphase spread analysis confirmed euploidy (Fig-
ures S1D–S1F and S2). Confocal fluorescence microscopy
followed by quantification indicated that short linker (SL)
cells, unlike long linker (LL), had cytoplasmic WT FUS-
eGFP (Figure 1F). Since FUS was WT, this was likely due
to disrupted function of the FUS NLS. Consistent with
the results from LL cells, P525L-eGFP in SL cells showedStem Cell Reports j Vol. 10 j 375–389 j February 13, 2018 377
higher levels of cytoplasmic mislocalization (Figures 1D
and 1F).
We further characterized our FUS-eGFP reporters to un-
derstand the mechanism of increased cytoplasmic FUS-
eGFP localization. qRT-PCR demonstrated that knocking
in the eGFP sequence in SL cells did not alter FUS expres-
sion levels (Figure 1G). Western blot (WB) analysis
confirmed production of the FUS-eGFP fusion protein in
LL and SL reporter lines. Blots probed with anti-FUS anti-
body revealed two bands of 75 and 100 kDa, corresponding
to the native and the fused protein, respectively (Figures 1H
and 1I), which demonstrated heterozygosity for the
reporter sequence. Blots probed with anti-eGFP antibody
showed one band at about 100 kDa, consistent with the
FUS-eGFP fusion protein (Figures S3A and S3B). Quantifica-
tion revealed reduced turnover of the FUS-eGFP protein
in SL reporter cells, especially in P525L, where FUS-
eGFP increased by about 1.2-fold compared with the WT
counterpart (Figure 1I). Because FUS RNA levels were un-
changed, this suggested that the SL eGFP tag as well as
the P525L mutation affects protein turnover by reducing
its clearance. Flow cytometry demonstrated that eGFP
was uniformly expressed by WT and P525L SL FUS-
eGFP cells in contrast to untargeted parental iPSCs, and
median fluorescence intensity confirmed increased signal
in mutant SL cells (Figure S3C). These trends were not
evident in LL FUS-eGFP lines (Figures 1H and S3A).
P525L Alters FUS-eGFP SG Dynamics
Since FUS was reported to be recruited into SGs, we tested
this in our iPSC models. iPSCs were treated with 0.5 mM
sodium arsenite for 1 hr and immunostained for eIF3 and
TIAR as eukaryotic SG markers (Figures 2A, S3D, and S3E).
In SL lines, >95% of WT and P525L FUS-eGFP subcellular
structures co-localized with eIF3 after arsenite treatment,
confirming FUS-eGFP recruitment (Figures 2A and 2B). LL
reporter lines behaved similarly, but FUS-eGFP was re-
cruited less abundantly than in SL iPSCs, particularly in
WT cells, where FUS-eGFP-positive SGs were almost imper-
ceptible (Figure S3D). These data suggest that SGs preferen-
tially recruit FUS-eGFP mislocalized to the cytoplasm, for
example, by the ALSmutation P525L or by disrupted inter-
action with nuclear transport proteins due to impaired NLS
function.
Our FUS-eGFP reporter lines are particularly powerful
because they enable monitoring endogenous FUS protein
dynamics in real time. Yet comparing the effects of WT
and mutant FUS on SG dynamics in LL reporter cells is
extremely challenging due to reduced FUS-eGFP recruit-
ment into SGs. In contrast, since SL mutant lines recapitu-
late a more exacerbated pathology, they may facilitate the
detection of phenotypes that would be too subtle in LL
lines. We also hypothesized that a treatment ameliorating378 Stem Cell Reports j Vol. 10 j 375–389 j February 13, 2018a disease phenotype in SL cells would also reduce disease-
associated phenotypes in the context of a less severe
pathology, such as that of LL cells. Therefore, to better
understand the effects of P525L FUS on SG dynamics
compared with WT FUS, we primarily focused on SL cells
and used LL lines for validation. Live-cell imaging
confirmed P525L FUS-eGFP mislocalization and recruit-
ment to SGs upon arsenite stress. When cells were heat
shocked, P525L FUS-eGFP iPSCs formed SGs at a lower
temperature (38.5C) compared with WT iPSCs (40C; Fig-
ure S4A), demonstrating that the P525Lmutation alters SG
dynamics.
To quantify SG dynamics, we developed a phenotypic
imaging assay that segmented each FUS-eGFP object and
assessed the following parameters: number of FUS-eGFP
objects per cell, area, and mean FUS-eGFP intensity. We
applied this assay to unstressed SL iPSCs with WT and
P525L FUS-eGFP (Figure S4B). Without added stress,
P525L FUS-eGFP iPSCs manifested significantly increased
numbers of FUS-eGFP objects per cell compared with WT
(Figure S4C; 1.83 versus 0.27 objects per cell; p = 6.1 3
105). P525L FUS-eGFP objects were significantly larger
(Figure S4D; 27.26 versus 18.12 pixels; p = 0.000143) and
had significantly increased average fluorescence intensity
(Figure S4E; 0.0111versus 0.0087 a.u.; p = 1.82 3 105)
compared with WT.
Subsequently, we quantified SGs in WT and P525L SL
FUS-eGFP iPSCs treated with 0.5 mM sodium arsenite
(Figure S4F). Since arsenite induced a diverse population
of SGs, individual FUS-eGFP SGs were divided into bins
according to area and intensity, and the relative frequency
of each bin was compared between WT and P525L. The
population of FUS-eGFP SGs with a relatively small area
(bin centers 60 through 140 pixels) was significantly less
frequent in P525L compared with WT (Figure 2C). In
contrast, there was a significant increase in the frequency
of FUS-eGFP SGs with a larger area (220–400 pixels). Both
trends becamemore striking when comparing populations
of FUS-eGFP SGs binned for mean intensity (Figure 2D).
Together, these data demonstrate that P525L leads to aber-
rant recruitment of FUS protein to SGs, which could be
seeding aggregate formation and cause MN degeneration
in FUS-ALS.
We investigated whether FUS-eGFP objects that formed
spontaneously without arsenite in SL iPSCs were SGs or,
if not, whether they had different characteristics from
SGs. Thus, we performed immunostaining for the SG
marker eIF3 and quantified its intensity within FUS-eGFP
objects with or without arsenite. Histogram analysis
showed that WT (Figure 2E) and P525L (Figure 2F) FUS-
eGFP objects had a significantly lower eIF3 intensity
comparedwith FUS-eGFP-positive SGs induced by arsenite.
In addition, FUS-eGFP objects that formed spontaneously
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Figure 2. Characterization of Stress
Granules in WT and P525L FUS-eGFP SL
iPSCs
(A) Confocal micrographs demonstrating
that iPSCs form FUS-eGFP SGs that
co-localize with eIF3. Scale bar, 20 mm.
(B–G) Quantification of SGs positive for
FUS-eGFP in WT and P525L iPSCs (B). Error
bars indicate SD. Histograms are shown for
the frequency of WT and P525L FUS-eGFP SG
area (C) and mean intensity (D). In contrast
to SGs, FUS-eGFP puncta do not co-localize
with eIF3-positive structures (E and F) and
display smaller size (G). Data represent
results from three independent experi-
ments.in the absence of arsenite (which we term ‘‘puncta’’ to
distinguish them from arsenite-induced SGs) were much
smaller compared with SGs. FUS-eGFP puncta were also
detected in LL P525L FUS-eGFP iPSCs, although less
frequently (Figure S4B).
Inhibition of PI3K/AKT/mTOR Pathway Ameliorates
Aberrant SG Dynamics
Compounds that modulate FUS SGs could represent novel
therapeutics for ALS. Exploiting the scalability of our FUS-
eGFP reporter lines, we performed a screening campaign
of 1,000 small molecules against known targets to inves-tigate the molecular mechanisms regulating FUS SG
dynamics in SL P525L FUS-eGFP iPSCs. Cells were treated
with each compound for 1 hr followed by addition of arse-
nite in the presence of the compound for an additional
hour. Sixty-nine compounds showed significant reduction
of the average FUS-eGFP area with a Z score < 3, giving a
hit rate of about 6.1% (Figure 3A). Among these were 13
compounds that inhibit PI3K, AKT, and mTOR, a signaling
pathway known to regulate autophagy, suggesting that in-
hibition of this pathway decreases FUS SG size in P525L
iPSCs, making themmore similar to theirWTcounterparts.
To confirm these results, we validated five of these hits atStem Cell Reports j Vol. 10 j 375–389 j February 13, 2018 379
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Figure 3. Identification of Compounds
Reducing P525L FUS-eGFP SG Area in SL
iPSCs
(A) Results for 1,000 compounds on
P525L FUS-eGFP SG area arranged in
ascending order. Compounds were consid-
ered as hits when Z < 3.
(B–D) Validation of selected compounds at
5 and 10 mM for their effects on P525L FUS-
eGFP SG area (B). Each time, images were
acquired from at least six positions/well
from three different wells per line. Error bars
indicate SEM. ****p < 0.0001. Example
micrographs are shown for DMSO control (C)
and selected hit compounds (D). Chemical
structures for the selected compounds were
downloaded from ChemSpider. Scale bar,
10 mm.two different concentrations (5 and 10 mM) and included
rapamycin, a well-characterized mTOR inhibitor. Consis-
tent with our primary screening results, each compound
at 5 mM showed a significant reduction in FUS-eGFP SG
area, and this reduction increased at 10 mM (Figures
3B–3D).We also performed a complete dose-response curve
for rapamycin, which showed the strongest effects at 15 mM
(data not shown).380 Stem Cell Reports j Vol. 10 j 375–389 j February 13, 2018We then treated SL P525L FUS-eGFP iPSCs with 15 mM
rapamycin for 120, 180, and 300min with 0.5 mM sodium
arsenite being included in the last 1 hr. FUS SGs were
analyzed as populations; individual SGs were segmented
(Figure 4A) and binned according to FUS-eGFP SG area or
mean intensity. The frequency of large FUS-eGFP-contain-
ing SGs was significantly decreased by rapamycin, while
the population of small FUS-eGFP SGs was significantly
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Figure 4. Rapamycin Treatment Amelio-
rates P525L FUS-eGFP SG Pathology in
SL iPSCs
(A) Confocal micrographs of P525L FUS-
eGFP iPSCs treated with 15 mM rapamycin for
time indicated. Arsenite was added for the
final 1 hr. Scale bar, 10 mm. Individual FUS-
eGFP drops were segmented and quantified
by binning. The relative frequency of each
bin was compared with 1 hr of arsenite only.
(B) Rapamycin treatment reduces P525L
FUS-eGFP droplet area.
(C) Rapamycin treatment reduces P525L
FUS-eGFP SG intensity.
(D and E) WT iPSCs respond more promptly
to rapamycin than P525L. (D) Droplet area.
(E) Intensity. n = 3 independent experi-
ments, and in each experiment images were
acquired from at least six positions/well
from four different wells per line.
Error bars indicate SEM. **p < 0.01,
***p < 0.001, and ****p < 0.0001.increased over time (Figure 4B). FUS-eGFP SG intensity
behaved similarly (Figure 4C). These data demonstrate
that mTOR inhibition reduces size and fluorescence inten-
sity of the population of P525L FUS-eGFP SGs.
Next, we quantified the effects of rapamycin on WT SL
FUS-eGFP SGs and compared them with P525L. As with
P525L, the frequency of large and bright WT FUS-eGFP
SGs significantly decreased upon rapamycin treatment,
while the frequency of small and dim SGs significantly
increased (Figures 4D and 4E). Although rapamycin
induced a comparable improvement, the dynamics of
this transition were clearly altered, as WT FUS-eGFP iPSCs
had a more rapid decrease in size and intensity. We specu-
late that mTOR inhibition may require more time to have
an effect in P525L cells because, in addition to forming
larger and more intense FUS-eGFP-containing objectscompared with WT upon arsenite treatment (Figures 2C
and 2D), P525L FUS-eGFP accumulates in puncta even
when unstressed (Figures S4B–S4E).
We further validated the effects of mTOR inhibition
using LL P525L FUS-eGFP reporter iPSCs. Cells were treated
with 15 mM rapamycin for 120 min with 0.5 mM sodium
arsenite being added for the last 1 hr (Figure S5A).
Compared with arsenite only, P525L FUS-eGFP SGs were
significantly smaller in the presence of rapamycin (Fig-
ure S5B) also in LL reporter lines, demonstrating that
mTOR inhibition ameliorates the FUS SG phenotype inde-
pendent of the linker.
We then assessed autophagy. WB analysis of iPSC lysates
showed strong LC3-II induction in the presence of 15 mM
rapamycin within a short incubation period (Figure S5C).
We analyzed autophagosome and lysosome distributionStem Cell Reports j Vol. 10 j 375–389 j February 13, 2018 381
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Figure 5. Induction of Autophagy Rescues P525L FUS-eGFP SG Pathology in iPSCs
(A) Confocal micrographs of WT and P525L FUS-eGFP SL iPSCs treated with 15 mM rapamycin for 5 hr. Arsenite was added for the final 1 hr.
LysoTracker red labels lysosomes, LC3 immunostaining highlights autophagosomes. Scale bar, 10 mm.
(legend continued on next page)
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using LC3 immunostaining in combination with Lyso-
Tracker red (LTR; Figure 5A). We observed LC3 puncta in
WT and P525L SL iPSCs in the presence of arsenite treat-
ment, with greater numbers inWTcells (Figure 5B). Consis-
tent with one report (Ganassi et al., 2016), we found less
than 1% of FUS-eGFP SGs immunostained positive for
LC3 in the presence of arsenite (Figure 5C). As expected,
rapamycin induced a significant increase in the number
of LC3 puncta per cell as well as a slight increase in LC3-
positive FUS-eGFP SGs. Yet, the overall percentage of
LC3-positive FUS-eGFP-containing SGs was less than
10%, which is too low to explain the effects of rapamycin
on the SG dynamics described above.
Rapamycin treatment also significantly increased the
number of lysosomes, measured as LTR-positive organelles.
However, no significant difference in the number of lyso-
somes was observed between WT and P525L with or
without arsenite (Figure 5D). Because eGFP is sensitive to
acidic conditions (Kneen et al., 1998), it should not
co-localize with LTR when properly incorporated in acidic
organelles for degradation. Accordingly, with arsenite
only, almost no co-localization was observed between WT
SL FUS-eGFP and LTR, which was even further reduced by
rapamycin treatment (Figure 5E). In contrast, we observed
a significant increase in the percentage of P525L FUS-eGFP
SGs positive for LTR compared with WT. Again, the overall
percentage of P525L FUS-eGFP was less than 5% and too
low to fully explain the observed effects of rapamycin on
SG dynamics as dependent on FUS SG degradation by
autophagy. Nevertheless, this co-localization suggested
impaired lysosomal degradation of P525L FUS-eGFP pro-
tein. Similarly, rapamycin significantly reduced the per-
centage of P525L FUS-eGFP SGs positive for LTR, but not
to the same level as WT. Together, these data suggest that
rapamycin may ameliorate FUS SG dynamics by degrading
FUS proteins that become aberrantly incorporated into
SGs, such as mislocalized cytoplasmic P525L FUS-eGFP,
rather than inducing the degradation of aberrant FUS SGs.
Rapamycin and Torkinib Ameliorate FUS SG
Phenotypes in iPSC-Derived Neurons
ALS is an MN disease so we extended our analysis from
iPSCs to iPSC-derived neurons. WT and P525L FUS-eGFP
iPSCs were differentiated into a mixed population of
neuronal cells containing MNs using a two-step protocol
(Figure S6A); iPSCswere differentiated into an intermediate(B) Two hours of rapamycin increases LC3 puncta per cell relative to
(C) Analysis of the frequency of LC3-positive FUS-eGFP SGs after 5 hr
(D) Increased frequency of LTR-positive puncta per cell upon rapamy
(E) Analysis of the frequency of LTR-positive FUS-eGFP SGs after rapam
independent experiments, and images were acquired from at least six
Error bars indicate SEM. *p < 0.05, ***p < 0.001, and ****p < 0.000population of expandable neural progenitor cells
(smNPCs) followed by MN specification. Immunostaining
demonstrated that WT and P525L smNPCs expressed the
neural progenitor markers NESTIN and SOX1 (Figure S6B),
while smNPC-derived neurons expressed MAP2, SMI32,
ISLET1, and HB9 (Figure S6C). Quantification of ISLET1
and HB9 positivity, which mark human MNs (Stifani,
2014), revealed that approximately 10%–15% of cultured
cells were MNs (Figures S6D and S6E); no difference was
observed in differentiation efficiency between WT and
P525L.
We applied our quantitative imaging assay to assess FUS-
eGFP in SL iPSC-derived neuronal cultures containingMNs
(Figure 6A). Without any stress, we observed more FUS-
eGFP puncta per cell in P525L relative to WT (Figure 6B).
Although statistical significance was not reached
(p = 0.056), this was likely due to the technical challenge
in quantifying objects in neuronal cell bodies, which are
much smaller and more compact compared with iPSCs.
When cultures of iPSC-derived neurons were treated with
0.5 mM arsenite for 1 hr, the number of FUS-eGFP objects
per cell significantly increased. We detected significantly
more FUS-eGFP SGs per cell and increased mean intensity
in P525L neurons compared with WT (Figures 6B and
6C). In contrast to iPSCs, the area of FUS-eGFP SGs in
neuronal cultures was significantly decreased in P525L
compared with WT (Figure 6D). We speculated that the
increased number of SGs per cell in P525L neurons may
indicate that SGs are more fragmented, which predicted
that the cumulative FUS-eGFP SG area within each cell
would increase in P525L neurons compared with WT. To
test this, we quantified the total area of FUS-eGFP SGs per
cell (Figure 6E) and confirmed our hypothesis (Figure 6E).
Rapamycin treatment ameliorated the phenotype for all
tested parameters, although P525L cells were never fully
rescued to WT levels. Because rapamycin induced a signif-
icant decrease in FUS-eGFP SG count per cell, mean inten-
sity, and cumulative area in neurons, this suggests an
important role for autophagy (Figures 6B–6E).
Autophagy was assessed in differentiated neurons using
WB analysis for the conversion of soluble LC3-I to lipid-
bound LC3-II. Here, we observed a clear increase in
LC3-II in the presence of 15 mM rapamycin after 24 hr of
treatment (Figure S5D). However, we found that LC3-II
increased in neurons much more slowly than in iPSCs.
Since rapamycin inhibits mTOR indirectly, differences inDMSO.
of rapamycin.
cin treatment for 2 hr relative to DMSO.
ycin treatment for 5 hr. All experiments used arsenite for 1 hr. n = 3
positions/well from four different wells per line.
1.
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Figure 6. Rapamycin Rescues P525L FUS-
eGFP SG Pathology in SL iPSC-Derived
Neurons
(A) Fluorescence confocal micrographs of
P525L FUS-eGFP iPSC-derived neurons
treated with 15 mM rapamycin in the pres-
ence of arsenite stress. Scale bar, 10 mm.
Individual FUS-eGFP objects were identified
and quantified. n = 3.
(B) Neurons with P525L FUS-eGFP have
significantly more SGs per cell compared
with WT and rapamycin reduces overall
numbers.
(C) Neurons with P525L FUS-eGFP have
significantly brighter SGs compared with
WT. Rapamycin significantly decreases the
brightness of WT and P525L FUS-eGFP SGs.
(D and E) P525L FUS-eGFP SGs in iPSC-
derived neurons are significantly smaller
compared with WT (D). However, total area
of FUS-eGFP SGs per cell is significantly
increased in neurons with P525L (E).
(F) Comparison of torkinib and rapamycin
effect on neuronal SG area. Torkinib (top)
significantly reduces SG area in both WT
(left) and P525L (right) FUS-eGFP neurons
after 5 hr of treatment. Rapamycin (bottom)
is effective at the tested concentration only
upon 24 hr treatment in P525L neurons
(right). Effects on SG area appear earlier in
WT cells (left), but are not as strong as
under torkinib treatment.
Error bars indicate SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p <
0.0001.the response may exist between cells. For this reason, we
also tested torkinib, which directly and selectively inhibits
mTOR by competingwith ATP.When neurons were treated
with 10 mM torkinib for a time frame of 5–30 hr, SL FUS-
eGFP SG area (Figure 6F) and intensity (data not shown)
of both WT and P525L FUS-eGFP neurons were signifi-
cantly reduced even upon the shortest treatment tested,
i.e., 5 hr. Therefore, compared with rapamycin treatment
performed under the same conditions (Figure 6F), torkinib
proved more efficacious, which was also confirmed in LL
FUS-eGFP neuronal cultures (Figure S7E). These results
corroborated the link between autophagy and SG dy-
namics and highlighted the importance of studying ALS384 Stem Cell Reports j Vol. 10 j 375–389 j February 13, 2018pathology in disease-relevant models, as the same com-
poundmay produce different effects in different cell types.
Stimulation of Autophagy Improves Neuronal
Survival
We assessed if induction of autophagy, which reduced
FUS-eGFP recruitment into SGs, would decrease neurode-
generation. We first immunostained neuronal cultures for
cleaved caspase-3 (CC3), which labels apoptotic cells, in
the presence or absence of rapamycin. For quantification,
we used an unbiased approach based on setting different
thresholds of CC3 intensity to define cells as ‘‘positive’’
for the apoptotic marker. We found that rapamycin
significantly reduced the percentage of CC3-positive P525L
SL FUS-eGFP neurons regardless of the selected threshold
(Figures S7A and S7B). Next, we investigated changes in
neuronal morphology by immunostaining neurons for
TUBB3 followed by quantification of neurite branch
length. Branch length is calculated as the connection be-
tween two crossing points. Thus, short branch lengths
identify denser networks, which are formed by healthy
neurons. Notably, rapamycin increased the number of
short branch segments (Figure S7C). Together, these data
show that autophagy stimulation reduces apoptosis in
cultures of differentiated neurons and promotes healthy
neuronal branching, consistent with improved survival.
Activation of Autophagy Rescues a DrosophilaModel
of FUS-ALS
We assessed the efficacy of inducing autophagy in vivo
using a transgenic animal model of FUS-ALS.We employed
a Drosophilamodel of ALS in which the neuronal ELAV-GS
(gene switch) drove conditional expression of WT and
P525L FUS throughout the CNS in adult animals. Consis-
tent with previous reports (Daigle et al., 2013; Lanson
et al., 2011), overexpression of WT and P525L FUS signifi-
cantly truncated the animals’ lifespan compared with
non-transgenic controls (Figure S7D). To induce auto-
phagy, UAS-Atg1 was expressed using the ELAV-GS driver.
Atg1 is a direct target of mTOR and positively regulates
the initiation of autophagy (Nakatogawa et al., 2009). As
per our small-molecule results, Atg1 overexpression signif-
icantly extended the lifespan of transgenic flies expressing
WT and P525L FUS (p < 0.0001; Figure S7D).
To further test the effects of autophagy stimulation on
FUS-ALS pathology, we looked at retinal degeneration in
our Drosophila model. We expressed WT or a disease-
causing mutation in FUS in the fly eyes using the GMR-
gal4 driver and found that overexpression of FUS led to
external degeneration as evident from necrotic patches,
loss of ommatidial organization, and depigmentation
(Figure S7E). When atg1 was ectopically expressed, the
eye degeneration phenotype was suppressed (Figures S7E
and S7F). These results came from Drosophila models of
FUS-ALS carrying other mutations than P525L, indicating
that inducing autophagy may be an effective strategy for
multiple ALS subtypes.
Clinically Approved Anti-depressants and Anti-
psychotics Ameliorate SG Phenotypes
We aimed to identify clinically approved drugs that could
reduce FUS-ALS SG phenotypes. SL P525L FUS-eGFP iPSCs
were treated for 1 hr with 1,600 US Drug Collection Mi-
croSource Discovery compounds at 10 mM each, followed
by addition of 0.5 mM arsenite for 1 hr (Figure 7A). FUS-
eGFP SG area was quantified and compared with controls.With 2.5 as a Z score threshold (p < 0.0124), 70 hit com-
pounds were identified, including sirolimus (rapamycin),
which corroborated our earlier results (Figures 7B and 7C).
Since MN cell bodies and dendrites are protected by the
blood-brain barrier, brain-penetrant drugs would be ideal
for treating ALS. Among the hits, we found a number of
brain-penetrant anti-psychotics/depressants that reduced
the area of P525L FUS-eGFP SGs induced by arsenite
(Figure 7D). These drug hits, including paroxetine, prome-
thazine, trimipramine, penfluridol, imipramine, and chlor-
promazine, were reported to induce autophagy (Tsvetkov
et al., 2010). Paroxetine and promethazine showed a trend
toward ameliorating arsenite-induced FUS-eGFP SGpheno-
types in SL P525L neurons (Figure 7E), although the effect
did not reach statistical significance. When paroxetine,
promethazine, and trimipramine were tested in the
context of a milder and more physiological phenotype,
such as that of P525L LL neurons, they produced a highly
significant reduction of FUS-eGFP SG intensity (Figures 7F
and 7G) and size (data not shown).DISCUSSION
Multiple proteins that are recruited to SGs, including FUS,
were shown to cause ALS when mutated. Thus, SGs are
hypothesized to be crucibles of FUS-ALS pathology (Li
et al., 2013). Because many of these same proteins impli-
cated in ALS also form aggregates in FTD, ALS and FTD are
considered related. FUS is particularly interesting because,
although aggregates are found in a subset of FTD patients,
these patients almost never harbor FUS mutations, which,
instead, are specifically associatedwithALS.Understanding
how improperly localized WT and/or mutated FUS protein
affects SG dynamics is critical for developing therapeutics.
As SGs are membraneless compartments, investigating
their behavior poses challenges. Here, we reported the first
real-time analysis of endogenous SG dynamics in iPSCs
and differentiated cultures of neurons including MNs. We
generated isogenic FUS-eGFP iPSC reporter lines using
CRISPR/Cas9n gene editing to knock in the ALS-causing
mutation P525L as well as a GFP tag at the C terminus of
the endogenous FUS protein. This approach is powerful
to investigate the effects of specific genetic traits, since
isogenic lines avoid variance caused by polymorphisms in
the genetic background as well as overexpression artifacts.
Since cytoplasmicmislocalization ofWTandmutant FUS
protein are both linked to neurodegeneration, we gener-
ated two different types of reporters. An LL FUS-eGFP
enabled monitoring native FUS protein, entirely nuclear
inWTreporter cells.When thesewere treatedwith arsenite,
SGs contained very weak levels of FUS-eGFP. Augmenting
the levels of cytoplasmic FUS-eGFP by knocking in eitherStem Cell Reports j Vol. 10 j 375–389 j February 13, 2018 385
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Figure 7. Identification of Drugs for Re-
purposing
(A–D) Chart of Z scores from drug screen
identifying US FDA-approved drugs able to
reduce SG area (A). Representative images
are shown for DMSO control in (B), sirolimus
in (C), and selected anti-depressants and
anti-psychotics in (D). Scale bars, 10 mm.
(E) SL P525L FUS-eGFP neurons treated with
chlorpromazine, paroxetine, promethazine,
and trimipramine show a slight reduction in
FUS SG intensity. Error bars represent SEM.
(F and G) LL P525L FUS-eGFP neurons treated
with the indicated compounds show a
reduction in FUS SG intensity (F), which is
significant for paroxetine, promethazine,
rapamycin, and torkinib as displayed in the
respective confocal micrographs (G). Scale
bar, 10 mm. n = 3 independent experiments
and in each experiment, images were ac-
quired from three positions/well from three
different wells per line. Error bars represent
SEM. **p < 0.01, ***p < 0.001, and
****p < 0.0001.the P525L mutation or an SL increased recruitment of FUS-
eGFP to SGs in the presence of arsenite. Together, this evi-
dence suggests that SGs preferentially recruit cytoplasmic
FUS, which can be increased through diverse mechanisms,
consistent with differences in the genetics of FUS-FTD and
FUS-ALS. SL P525L FUS-eGFP cells showed the most severe
phenotype and spontaneously formed subcellular struc-
tures under unstressed conditions. In contrast to arsenite-
induced SGs, these objects were eIF3 negative and rela-
tively small. To distinguish these objects from SGs, we
termed them puncta, and we speculate that FUS aggregates
may also arise from puncta independent of canonical SG
formation.
It has been demonstrated that misfolded proteins as well
as mutant FUS protein accumulate in SGs, which may be386 Stem Cell Reports j Vol. 10 j 375–389 j February 13, 2018linked to aggregation (Ganassi et al., 2016; Patel et al.,
2015). Consistent with this, we found that SGs showed
greater recruitment of P525L FUS-eGFP compared with
WT, leading to aberrant FUS SG dynamics. The life cycle
of SGs can be broken down into multiple steps (Protter
and Parker, 2016). First, nucleation occurs in the presence
of oligomeric assemblies of messenger ribonucleoproteins
(mRNPs). Next, the nucleated states increase in size by
the addition of further mRNPs. In mammals, a third step
is the merging of smaller SGs to form higher-order assem-
blies via mechanisms relying on microtubule-dependent
transport. In iPSCswithmutant FUS-eGFP,we observed for-
mation of SGs more rapidly compared with WT, as well as
larger SGs. These observations suggest that in iPSCs, the
sequence of steps is followed, but that mutant cells form
large-sized, later-stage SGs faster than WT due to their
intrinsic inclination to coalesce in aggregates caused by
P525L-induced FUS mislocalization. Interestingly, while
total FUS SG area was increased in neurons with mutant
FUS, neuronal SGs were more fragmented compared with
WT, suggesting a significantly decreased efficiency in
coalescence, the last step of SG formation dependent on
microtubule transport. Consistent with this, RNPs contain-
ing FUS are transported in MN axons (Schoen et al., 2015),
and disruptions in microtubule transport are linked to ALS
pathogenesis (Munch et al., 2004).
iPSCs’ ability to limitlessly self-renew makes them ideal
for drug screening. Thus, we used our FUS-eGFP reporter
lines to identify small molecules with known targets, as
well as approved drugs, that ameliorated SG phenotypes
induced by P525L. Inhibition of the PI3K/AKT/mTOR
pathway at different levels decreased FUS-eGFP SG
numbers, area, and intensity, resembling WT conditions.
The mTOR pathway is notoriously associated with a
plethora of biological functions, including cell growth,
proliferation, and survival. However, becausemTOR kinase
is amaster regulator of autophagy induction, and defects in
autophagy are prominent in diverse disease states such as
neurodegenerative diseases, we explored the possibility of
a mechanistic link between autophagy and SG dynamics.
In contrast to one report (Ryu et al., 2014), we observed
that only a small fraction of WT or P525L FUS-eGFP SGs
were positive for LC3, indicating that very few SGs are
degraded by autophagy. Similarly, Buchan et al. reported
that disruption of autophagy increased SG formation, but
this was linked to decreased SG clearance, resulting in their
accumulation (Buchan et al., 2013). In contrast, our find-
ings extend the results of Ganassi et al. (2016) by showing
that triggering autophagy prior to SG induction amelio-
rates phenotypes in a dose- and time-dependent manner,
without a significant fraction of SGs undergoing auto-
phagy.We speculate this may be due to increased clearance
of soluble mislocalized FUS proteins that would otherwise
be incorporated into SGs. Further experiments are neces-
sary to better characterize the interplay between autophagy
and SG dynamics. Our observation that mTOR inhibition
decreased the levels of CC3 and increased neuronal
network arborization enables these mechanistic studies to
be linked to human neurodegeneration.
Direct inhibition of mTOR proved beneficial in our cell-
based experimental setup. However, rapamycin (or simi-
larly, torkinib) administration is unlikely to be a viable
clinical strategy for ALS because it is a potent immunosup-
pressant. Previously, rapamycin was shown to exacerbate
ALS pathology in a mouse model of ALS, and it was benefi-
cial only when lymphocytes were depleted (Staats et al.,
2013). Thus, we also screened a library of clinically
approved drugs to identify other potentially interestingcompounds. We found multiple anti-depressants and
anti-psychotics, whosemechanism of actionwas suggested
to be independent of mTOR (Park et al., 2014; Tsvetkov
et al., 2010). At least one of these drugs, paroxetine, was
shown to ameliorate Huntington’s and Alzheimer’s pathol-
ogy in mice, corroborating the idea that modulation of
autophagy is beneficial in the context of neurodegenera-
tive diseases. The identified drugs are brain penetrant and
their effects well characterized. Importantly, prometha-
zine, and chlorpromazine share the same chemical
scaffold, which is directly related to the tricyclic structure
of trimipramine and imipramine. This could be an ideal
starting point for medicinal chemistry to optimize a novel
compound that specifically ameliorates FUS pathology in
ALS patients. It is important to note that increasing auto-
phagy protected neurons against mutant TDP-43, suggest-
ing that these compounds might be beneficial for multiple
forms of ALS (Barmada et al., 2014). However, because our
data link induction of autophagy to neuroprotection, it will
may be necessary to administer these treatments when
MNs are still functionally attached to skeletal muscle, i.e.,
upon diagnosis, and earlier diagnosis may be required, for
instance, using gene sequencing, before symptom onset.EXPERIMENTAL PROCEDURES
Gene Editing
Dr. Boris Greber donated the guide RNA expression vector. Donor
vectors were synthesized (Integrated DNA Technologies). iPSCs
used in this project were previously generated (see Supplemental
Information). A 1:1 mix of donor construct and guide RNA was
used to transfect 175,000 iPSCs with FuGENE HD Transfection
Reagent (Promega). Neural progenitor cells and neurons were
derived as previously described (Reinhardt et al., 2013).
Immunocytochemistry Staining
Cells were fixed for 20 min with 4% paraformaldehyde (EM
Sciences). Permeabilization and blocking were performed using
0.1% Triton X-100 (Sigma), 10% fetal calf serum (GE Healthcare),
and 1% BSA in PBS (Lonza). Primary antibodies were applied over-
night at 4C. Secondary antibodies were applied for 1 hr at room
temperature.
Compound Screening Protocol
iPSCswere seeded ontoGreiner mClear 384-well plates. Compounds
were added thenextdayat afinal concentrationof 10mM.After 1hr,
cells were stressedwith 500 mMsodium arsenite. Subsequently, cells
were fixed with 3.7% formaldehyde and stained with Hoechst and
CellMask blue. Plates were imaged with Yokogawa Cell Voyager
CV7000 at 403magnification.
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